SCHEMBL2930232

SCHEMBL2930232

Cn1cc2c(-c3ccccc3)c(-c3ccncc3)c(-c3ccccc3)nc2n1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 8/20 0.48
ADORA1 P30542 4/20 0.48
ADORA2A P29274 4/20 0.43
NSD3 Q9BZ95 1/20 0.41
BRAF P15056 4/20 0.41
ADORA2B P29275 1/20 0.41
MAPK13 O15264 2/20 0.40
MAPK12 P53778 2/20 0.40
MAPK11 Q15759 2/20 0.40
MAPK14 Q16539 2/20 0.40
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
NOTUM Q6P988 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386962 0.86 MAPK14 (0.57) ADORA3ADORA1ADORA2ABRAFADORA2B
SCHEMBL1384721 0.84 MAPK14 (0.48) ADORA3ADORA1ADORA2ABRAFADORA2B
SCHEMBL29652641 0.83 ADORA2A (0.39) ADORA3ADORA1ADORA2ANSD3BRAF
SCHEMBL1384574 0.83 MAPK14 (0.39) ADORA3ADORA1ADORA2ANSD3BRAF
SCHEMBL1384930 0.81 MAPK14 (0.51) ADORA3ADORA1ADORA2ABRAFADORA2B
SCHEMBL1385083 0.81 MAPK14 (0.46) ADORA3ADORA1ADORA2ABRAFADORA2B
SCHEMBL1385243 0.81 ADORA2A (0.42) ADORA3ADORA1ADORA2ANSD3BRAF
SCHEMBL1384405 0.81 CSNK1D (0.40) ADORA3ADORA1ADORA2ABRAFMAPK14
SCHEMBL1386614 0.80 PDE10A (0.49) MAPK13MAPK12MAPK11MAPK14CSNK1D
SCHEMBL1387083 0.79 MAP4K4 (0.46) ADORA3ADORA1ADORA2ABRAFMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 ADORA3 3983/4885ADORA1 4004/4885ADORA2A 3463/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA3 4277/4885ADORA1 4368/4885ADORA2A 3970/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 ADORA3 4277/4885ADORA1 4368/4885ADORA2A 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.